Wael Elmallah, MD
Interventional Cardiology · New Britain, CTNPI 1487861712
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 276 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations.
Across 276 payments — averaging $32.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Abbott$893
- Amgen$752
- Edwards Lifesciences$550
- Johnson & Johnson$543
- Novo Nordisk$446
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,838100%
- Education$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 49 | $1,806 |
| Abbott | 25 | $893 |
| Amgen | 15 | $752 |
| Edwards Lifesciences | 10 | $550 |
| Johnson & Johnson(2 entities) | 17 | $543 |
| Novo Nordisk | 12 | $446 |
| Medtronic(2 entities) | 22 | $399 |
| Novartis | 16 | $320 |
| Pfizer | 12 | $279 |
| Impulse Dynamics (USA) Inc. | 10 | $274 |
| Boehringer Ingelheim | 8 | $249 |
| Heartflow, Inc. | 6 | $220 |
| Actelion Pharmaceuticals US, Inc. | 8 | $205 |
| AstraZeneca | 10 | $195 |
| Atricure, Inc. | 1 | $188 |
| Abiomed | 4 | $143 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $130 |
| Biotronik Inc. | 2 | $130 |
| Terumo Medical Corporation | 1 | $128 |
| Alnylam Pharmaceuticals Inc. | 5 | $118 |
| Lexicon Pharmaceuticals, Inc. | 5 | $108 |
| E.r. Squibb & Sons, L.L.C. | 6 | $105 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $91 |
| Opsens Inc. | 1 | $83 |
| Merck | 4 | $78 |
| Inari Medical, Inc. | 1 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Esperion Therapeutics, Inc. | 2 | $48 |
| Bayer | 2 | $39 |
| Cvrx, Inc. | 1 | $34 |
| Bridgebio Pharma, Inc. | 1 | $31 |
| GSK | 1 | $26 |
| Vifor Pharma, Inc. | 1 | $22 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Preventice Services, LLC | 1 | $19 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $19 |
| Scpharmaceuticals Inc. | 1 | $16 |
| Siemens Medical Solutions USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$292
- XARELTO$254
- WATCHMAN Access System$248
- Repatha$205
- EPI-SENSE GUIDED COAGULATION SYS$188
- Watchman$147
- Edwards SAPIEN 3 Transcatheter Heart Valve$144
- CardioMEMS HF System$143
- TR Band$128
- Ozempic$121
- CARDIOMEMS$115
- JARDIANCE$112
- BioMonitor$112
- Edora 8 DR-T$112
- Rivacor 7 DR-T$112
- Acticor 7 VR-T DX$112
How this compares
$8,860 in reported general payments places this provider in the 60th percentile of 73 interventional cardiology providers in Connecticut.
See all interventional cardiology providers in Connecticut →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 128 | $167,591 |
| EntrestoSacubitril/Valsartan | 83 | $125,565 |
| JardianceEmpagliflozin | 52 | $77,941 |
| FarxigaDapagliflozin Propanediol | 66 | $71,049 |
| OzempicSemaglutide | 53 | $58,982 |
| BrilintaTicagrelor | 51 | $52,226 |
| Repatha SureclickEvolocumab | 28 | $16,262 |
| Nebivolol Hcl | 62 | $5,121 |
| Metoprolol Succinate | 229 | $3,950 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 198 | $3,661 |
| ClopidogrelClopidogrel Bisulfate | 191 | $1,846 |
| Valsartan | 85 | $1,385 |
| Colchicine | 15 | $1,381 |
| Torsemide | 71 | $1,259 |
| Atorvastatin Calcium | 84 | $918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $279 | $167,591128 claims |
| NovartisEntresto | $320 | $125,56583 claims |
| AstraZenecaFarxiga, Brilinta | $195 | $123,275117 claims |
| Boehringer IngelheimJardiance | $249 | $77,94152 claims |
| Novo NordiskOzempic | $446 | $58,98253 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 73 interventional cardiology providers in Connecticut.
Other interventional cardiology in New Britain
- Robert BorkowskiNew Britain$8K
- Manny KatsetosNew Britain$7K
- Aaron BriceNew Britain$6K
- Amit VoraNew Haven$409K
- Craig ThompsonHartford$222K
- Michael NannaNew Haven$60K
- Jawad HaiderBloomfield$44K
- Sameer NagpalNew Haven$43K
- Khagendra DahalFarmington$42K
- Abdul QaziHartford$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.